Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,547 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00536991 | Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer | terminated | Phase 1 / Phase 2 | 51 | Roswell Park Cancer InstituteOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00084864 | Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate | terminated | Phase 2 | 25 | Roswell Park Cancer InstituteOTHER | 1 | Jun 12, 2017 |
| clinicaltrials |
| NCT01558492 | Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer | terminated | Phase 2 | 3 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT01023061 | Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer(RAD1) | completed | Phase 2 | 24 | University of WashingtonOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT01338012 | Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer(mCRPC) | terminated | Phase 2 | 8 | DendreonINDUSTRY | 1 | Jun 5, 2017 | clinicaltrials |
| NCT00225420 | Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer(NRR) | completed | Phase 1 / Phase 2 | 23 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT01316458 | Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy | completed | Phase 2 | 51 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 1, 2017 | clinicaltrials |
| NCT01431391 | Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer | completed | Phase 2 | 68 | DendreonINDUSTRY | 1 | May 30, 2017 | clinicaltrials |
| NCT00658697 | Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer | completed | Phase 2 | 42 | Dana-Farber Cancer InstituteOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT00486642 | Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | May 24, 2017 | clinicaltrials |
| NCT02105675 | Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 60 | SOTIO a.s.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT02107391 | Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer | completed | Phase 2 | 63 | SOTIO a.s.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT02107404 | Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer | completed | Phase 2 | 150 | SOTIO a.s.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT02137746 | Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer | completed | Phase 2 | 24 | SOTIO a.s.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT00715078 | To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen | completed | Phase 2 | 122 | DendreonINDUSTRY | 1 | May 23, 2017 | clinicaltrials |
| NCT00901342 | Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer | completed | Phase 2 | 104 | DendreonINDUSTRY | 1 | May 23, 2017 | clinicaltrials |
| NCT01385293 | BKM120 in Metastatic Castration-resistant Prostate Cancer | terminated | Phase 2 | 30 | Andrew J. Armstrong, MDOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00170157 | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | completed | Phase 2 | 112 | Mayo ClinicOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT01215032 | Metformin in Castration-Resistant Prostate Cancer | terminated | Phase 2 | 21 | Massachusetts General HospitalOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT01735396 | Abiraterone Acetate Trial in African American Prostate Cancer Patients | terminated | Phase 2 | 11 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT02022371 | Prostate Cancer Genomic Heterogeneity(PROGENY) | completed | Phase 1 / Phase 2 | 50 | University College London HospitalsOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01641185 | Ion Prostate Irradiation(IPI) | completed | Phase 2 | 92 | Heidelberg UniversityOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT01828476 | Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer | terminated | Phase 2 | 13 | Rutgers, The State University of New JerseyOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT00182741 | Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 19 | OHSU Knight Cancer InstituteOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT03137186 | Repurposing Metformin as Anticancer Drug: in Advanced Prostate Cancer(Mansmed) | unknown | Phase 2 | 120 | Mansoura UniversityOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT00003781 | Docetaxel in Treating Patients With Stage IV Prostate Cancer | completed | Phase 2 | 25 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00004043 | Calcitriol in Treating Patients With a Rising PSA Level Following Treatment for Prostate Cancer | completed | Phase 2 | 25 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00017563 | Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer | completed | Phase 2 | 57 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00017576 | Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 19 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00459810 | Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer | terminated | Phase 2 | 21 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00482274 | Docetaxel in Treating Patients With Relapsed Prostate Cancer | terminated | Phase 2 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01228084 | Sulforaphane in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02840162 | Pre-Prostatectomy Celecoxib or Placebo | terminated | Phase 2 | 34 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02212197 | Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer | completed | Phase 2 | 51 | Camurus ABINDUSTRY | 2 | Apr 25, 2017 | clinicaltrials |
| NCT03124615 | Effect of Enzalutamide Dose Reduction on Fatigue, Cognition, and Drug Trough Levels in Patients With Prostate Cancer(EFFECT) | unknown | Phase 2 | 47 | Macquarie University, AustraliaOTHER | 1 | Apr 24, 2017 | clinicaltrials |
| NCT00669656 | Herbal Therapy for Treatment of Recurrent Prostate Cancer | completed | Phase 2 | 43 | University of Southern CaliforniaOTHER | 1 | Apr 20, 2017 | clinicaltrials |
| NCT02016040 | Focal Therapy Using HIFU for Localised Prostate Cancer | unknown | Phase 2 / Phase 3 | 25 | Jewish General HospitalOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT00118092 | 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT02135445 | Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer | completed | Phase 2 | 103 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Apr 13, 2017 | clinicaltrials |
| NCT00574769 | Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer | completed | Phase 1 / Phase 2 | 27 | University of Southern CaliforniaOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT01450683 | Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy | terminated | Phase 2 | 4 | Stanford UniversityOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT02440308 | 68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer | completed | Phase 2 | 10 | Stanford UniversityOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT00895310 | Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy | completed | Phase 2 | 30 | University of California, DavisOTHER | 1 | Mar 30, 2017 | clinicaltrials |
| NCT00769795 | Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer | completed | Phase 2 | 29 | University of WashingtonOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01317641 | Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 136 | Orion Corporation, Orion PharmaINDUSTRY | 6 | Mar 29, 2017 | clinicaltrials |
| NCT01695044 | A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC) | completed | Phase 2 | 119 | Progenics Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 24, 2017 | clinicaltrials |
| NCT02020135 | An Open-label Extension Study of PSMA ADC 2301 in mCRPC | completed | Phase 2 | 9 | Progenics Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 24, 2017 | clinicaltrials |
| NCT02656615 | Abiraterone-Rechallenge Study for CRPC Patients(ABI-RE) | terminated | Phase 2 | 4 | Aurelius OmlinOTHER | 1 | Mar 24, 2017 | clinicaltrials |
| NCT02483884 | PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer | terminated | Phase 1 / Phase 2 | 30 | Lantheus Biosciences Ltd.INDUSTRY | 2 | Mar 22, 2017 | clinicaltrials |
| NCT03085966 | Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC | unknown | Phase 1 / Phase 2 | 30 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Jun 14, 2017source: clinicaltrials